Report

Update: FY14 results confirm progress as expected

Simavita’s FY14 results highlight the progress being achieved, with the launch in the important US market tracking in line with our expectations. The proprietary SIM (Smart Incontinence Management) platform appears to have been well received among the key early adopters, where its ability to improve the outcomes and costs associated with urinary incontinence in residential care settings has been understood. The next 12 to 18 months should mark the defining events on Simavita’s journey towards sustainable profitability. Our DCF model suggests a valuation of A$107m.
Underlying
Simavita - CDI

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch